Quizartinib HCl - CAS 1132827-21-4

Quizartinib, also know as AC220 and AC010220, is an orally available FLT3 / STK1 inhibitor with potential antineoplastic activity. Class III receptor tyrosine kinase inhibitor AC220 selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases.

Others, FLT, Apoptosis, Ligands for Target Protein for PROTAC

Angiogenesis, Apoptosis, PROTAC, Others, Tyrosine Kinase/Adaptors

1132802

C29H34Cl2N6O4S

633.59

O(CCN1CCOCC1)C=2C=C3C(N4C(S3)=NC(=C4)C5=CC=C(NC(NC=6C=C(C(C)(C)C)ON6)=O)C=C5)=CC2.Cl.Cl

-20°C

Ice Packs

Small Compound